Lntrio 10 Tablet is a combination antihypertensive medication containing Telmisartan 40mg, Cilnidipine 10mg, and Chlorthalidone 12.5mg. Telmisartan is an angiotensin II receptor blocker (ARB) that helps relax blood vessels by inhibiting the effects of angiotensin II, thereby reducing blood pressure. Cilnidipine is a calcium channel blocker that selectively inhibits L-type and N-type calcium channels, leading to vasodilation and decreased peripheral resistance. Chlorthalidone is a thiazide-like diuretic that promotes sodium and water excretion, reducing blood volume and subsequently lowering blood pressure. This combination is indicated for the management of essential hypertension, particularly in patients requiring multi-mechanistic approaches to achieve optimal blood pressure control. By targeting different pathways involved in blood pressure regulation, Lntrio 10 Tablet offers enhanced efficacy in reducing cardiovascular risks associated with hypertension, such as stroke, myocardial infarction, and heart failure. The medication should be administered under medical supervision with regular monitoring of blood pressure, renal function, and electrolytes to avoid potential adverse effects such as hypotension, electrolyte imbalance, or renal impairment. Lntrio 10 Tablet is contraindicated in patients with hypersensitivity to any component, severe renal or hepatic impairment, and pregnancy. Adherence to prescribed dosing and lifestyle modifications is essential for effective hypertension management with this combination therapy.